{"id":812,"date":"2021-09-24T16:16:37","date_gmt":"2021-09-24T07:16:37","guid":{"rendered":"https:\/\/jcog-btsg.jp\/?page_id=812"},"modified":"2021-10-07T17:38:52","modified_gmt":"2021-10-07T08:38:52","slug":"exam","status":"publish","type":"page","link":"https:\/\/jcog-btsg.jp\/en\/research\/exam\/","title":{"rendered":"Test List"},"content":{"rendered":"

<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Test No.<\/th>\nTest Type<\/th>\nTest name<\/th>\nTest Outline<\/th>\n<\/tr>\n
JCOG1910A1<\/td>\nAccompanying Research<\/td>\nAn Exploratory Study on Prognostic Biomarkers in Elderly Patients with Primary Glioblastoma<\/td>\n<\/i><\/a><\/td>\n<\/tr>\n
JCOG1910<\/td>\nPhase III trials<\/td>\nA Randomized, Controlled Phase III Study of Oligofractionated Radiotherapy with Temozolomide for Elderly Patients with Primary Glioblastoma<\/td>\n<\/i><\/a><\/td>\n<\/tr>\n
JCOG1703<\/td>\nPhase III trials<\/td>\nA Randomized Phase III Trial of Radical Ablation + Implantation of Carmustine for Intracerebral Implantation + Temozolomide Chemoradiation versus Radical Ablation + Temozolomide Chemoradiation for Primary Glioblastoma<\/td>\n<\/i><\/a><\/td>\n<\/tr>\n
JCOG1308C<\/td>\nPhase III trials<\/td>\nA Multicenter, Randomized Phase III Trial Comparing Dose-Enhanced Temozolomide + Bevacizab Therapy in Recurrent Glioblastoma<\/td>\n<\/i><\/a><\/td>\n<\/tr>\n
JCOG1303B<\/td>\nIndividual Banking<\/td>\nJCOG-Biobank Japan collaborative biobank Frozen tissue and blood banking of patients enrolled in JCOG1303<\/td>\n<\/i><\/a><\/td>\n<\/tr>\n
JCOG1303<\/td>\nPhase III trials<\/td>\nA Randomized Phase III Trial Comparing Radiation Alone and Radiation Therapy with Temozolomide for WHO Grade II Astrocytoma with Residual Tumor after Surgery<\/td>\n<\/i><\/a><\/td>\n<\/tr>\n
JCOG1114CA1<\/td>\nAccompanying Research<\/td>\nAn exploratory study of PCNSL prognostic biomarkers and determinants of response to therapy by analysis of clinical specimens<\/td>\n<\/i><\/a><\/td>\n<\/tr>\n
JCOG1114C<\/td>\nPhase III trials<\/td>\nA randomized controlled trial of preirradiation high-dose methotrexate plus radiotherapy versus preirradiation high-dose methotrexate plus concomitant radiotherapy with temozolomide plus maintenance temozolomide for first primary malignant lymphoma of the central nervous system<\/td>\n<\/i><\/a><\/td>\n<\/tr>\n
JCOG1016B<\/td>\nIndividual Banking<\/td>\nJCOG-Biobank Japan collaborative biobank Frozen tissue and blood banking of patients enrolled in JCOG1016<\/td>\n<\/i><\/a><\/td>\n<\/tr>\n
JCOG1016<\/td>\nPhase III trials<\/td>\nA Randomized Phase III Trial Comparing Postoperative Nimustine Hydrochloride (ACNU) Chemoradiation with Temozolomide Chemoradiation at Prior Recurrence in Primary Anaplastic Glioma<\/td>\n<\/i><\/a><\/td>\n<\/tr>\n
JCOG0911A2<\/td>\nAccompanying Research<\/td>\nA study of MRI-based treatment response and MRI-based prognosis prediction for glioblastoma treated with chemoradiotherapy<\/td>\n<\/i><\/a><\/td>\n<\/tr>\n
JCOG0911A1<\/td>\nAccompanying Research<\/td>\nA Study of Predictive and Prognostic Factors in Glioblastoma Patients Treated with Chemotherapy and Radiation Therapy<\/td>\n<\/i><\/a><\/td>\n<\/tr>\n
JCOG0911<\/td>\nRandomized phase II trial<\/td>\nA Randomized Phase II Trial of Interferon-beta plus Temozolomide Chemoradiotherapy for Primary Glioblastoma<\/td>\n<\/i><\/a><\/td>\n<\/tr>\n
JCOG0504<\/td>\nPhase III trials<\/td>\nA Randomized Comparison of Tumor Resection + Whole Brain Irradiation versus Tumor Resection + Salvage Radiation Therapy for Metastatic Brain Tumors<\/td>\n<\/i><\/a><\/td>\n<\/tr>\n
JCOG0305<\/td>\nPhase II\/III trials<\/td>\nA Randomized Phase II\/III Study of ACNU Alone vs. Procarbazine + ACNU Combination as Radiochemotherapy for Grades 3 and 4 Astrocytoma<\/td>\n<\/i><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u9069\u5408\u4ef6\u6570\uff1a15<\/p>\n

<\/p>","protected":false},"excerpt":{"rendered":"

Research<\/h2>\n